{"entity":{"type":"insider","cik":"0001579829","url":"/insider/0001579829","json_url":"/insider/0001579829.json","name":"Ignelzi Troy A.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":53,"n_filings":22,"first":"2020-03-04","last":"2025-03-13","span_basis":"filed_date"},"name_variants":[{"name":"Ignelzi Troy A.","source":"filing","n_filings":22,"first_seen":"2020-03-04","last_seen":"2025-03-13"}],"transactions":[{"id":4312386,"accession":"0000950170-25-038878","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-038878","line_url":"/filing/0000950170-25-038878#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Rapport Therapeutics, Inc.","issuer_ticker":"RAPP","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":9.98,"price_display":"9.98","price_state":"stated","total_value":998.0,"total_display":"998.00","total_whole":"998","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-13","filed_date":"2025-03-13","scope":"insider"},{"id":4312381,"accession":"0000950170-25-038878","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-038878","line_url":"/filing/0000950170-25-038878#line-1","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Rapport Therapeutics, Inc.","issuer_ticker":"RAPP","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9900.0,"shares_display":"9,900","price_per_share":10.1,"price_display":"10.10","price_state":"stated","total_value":99990.0,"total_display":"99,990.00","total_whole":"99,990","shares_owned_after":9900.0,"shares_owned_after_display":"9,900","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-03-12","filed_date":"2025-03-13","scope":"insider"},{"id":8465246,"accession":"0000950170-23-044413","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000950170-23-044413","line_url":"/filing/0000950170-23-044413","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":175.1217,"price_display":"175.12","price_state":"stated","total_value":262682.55,"total_display":"262,682.55","total_whole":"262,683","shares_owned_after":31052.0,"shares_owned_after_display":"31,052","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-22","filed_date":"2023-08-24","scope":"insider","n_lines":4},{"id":7995239,"accession":"0000950170-23-024286","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0000950170-23-024286","line_url":"/filing/0000950170-23-024286","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9000.0,"shares_display":"9,000","price_per_share":223.40685222222223,"price_display":"223.41","price_state":"stated","total_value":2010661.67,"total_display":"2,010,661.67","total_whole":"2,010,662","shares_owned_after":33361.0,"shares_owned_after_display":"33,361","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-23","filed_date":"2023-05-25","scope":"insider","n_lines":6},{"id":8715139,"accession":"0001593968-23-000345","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-23-000345","line_url":"/filing/0001593968-23-000345#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6000.0,"shares_display":"6,000","price_per_share":190.01,"price_display":"190.01","price_state":"stated","total_value":1140060.0,"total_display":"1,140,060.00","total_whole":"1,140,060","shares_owned_after":30487.0,"shares_owned_after_display":"30,487","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-21","filed_date":"2023-02-23","scope":"insider"},{"id":8375953,"accession":"0001593968-23-000170","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-23-000170","line_url":"/filing/0001593968-23-000170#line-4","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":200.14,"price_display":"200.14","price_state":"stated","total_value":40028.0,"total_display":"40,028.00","total_whole":"40,028","shares_owned_after":21837.0,"shares_owned_after_display":"21,837","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-18","filed_date":"2023-01-19","scope":"insider"},{"id":8375945,"accession":"0001593968-23-000170","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-23-000170","line_url":"/filing/0001593968-23-000170#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":817.0,"shares_display":"817","price_per_share":201.41,"price_display":"201.41","price_state":"stated","total_value":164551.97,"total_display":"164,551.97","total_whole":"164,552","shares_owned_after":21837.0,"shares_owned_after_display":"21,837","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-17","filed_date":"2023-01-19","scope":"insider"},{"id":6550921,"accession":"0001593968-22-001609","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-22-001609","line_url":"/filing/0001593968-22-001609#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16500.0,"shares_display":"16,500","price_per_share":225.85,"price_display":"225.85","price_state":"stated","total_value":3726525.0,"total_display":"3,726,525.00","total_whole":"3,726,525","shares_owned_after":9970.0,"shares_owned_after_display":"9,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-15","filed_date":"2022-11-17","scope":"insider"},{"id":6550909,"accession":"0001593968-22-001490","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001593968-22-001490","line_url":"/filing/0001593968-22-001490#line-8","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":233.2,"price_display":"233.20","price_state":"stated","total_value":93280.0,"total_display":"93,280.00","total_whole":"93,280","shares_owned_after":9970.0,"shares_owned_after_display":"9,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-04","filed_date":"2022-10-04","scope":"insider"},{"id":6550906,"accession":"0001593968-22-001490","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001593968-22-001490","line_url":"/filing/0001593968-22-001490","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4100.0,"shares_display":"4,100","price_per_share":231.17560975609757,"price_display":"231.18","price_state":"stated","total_value":947820.0,"total_display":"947,820.00","total_whole":"947,820","shares_owned_after":11470.0,"shares_owned_after_display":"11,470","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-03","filed_date":"2022-10-04","scope":"insider","n_lines":3},{"id":6550896,"accession":"0001593968-22-001490","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-22-001490","line_url":"/filing/0001593968-22-001490","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10500.0,"shares_display":"10,500","price_per_share":228.8587342857143,"price_display":"228.86","price_state":"stated","total_value":2403016.71,"total_display":"2,403,016.71","total_whole":"2,403,017","shares_owned_after":14503.0,"shares_owned_after_display":"14,503","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-09-30","filed_date":"2022-10-04","scope":"insider","n_lines":4},{"id":6256257,"accession":"0001593968-22-001335","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-22-001335","line_url":"/filing/0001593968-22-001335#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16500.0,"shares_display":"16,500","price_per_share":227.83,"price_display":"227.83","price_state":"stated","total_value":3759195.0,"total_display":"3,759,195.00","total_whole":"3,759,195","shares_owned_after":24970.0,"shares_owned_after_display":"24,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-09","filed_date":"2022-08-11","scope":"insider"},{"id":6687505,"accession":"0001593968-22-000886","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001593968-22-000886","line_url":"/filing/0001593968-22-000886#line-6","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40.0,"shares_display":"40","price_per_share":134.46,"price_display":"134.46","price_state":"stated","total_value":5378.4,"total_display":"5,378.40","total_whole":"5,378","shares_owned_after":24970.0,"shares_owned_after_display":"24,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-21","filed_date":"2022-04-21","scope":"insider"},{"id":6687501,"accession":"0001593968-22-000886","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-22-000886","line_url":"/filing/0001593968-22-000886#line-4","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":704.0,"shares_display":"704","price_per_share":133.2,"price_display":"133.20","price_state":"stated","total_value":93772.8,"total_display":"93,772.80","total_whole":"93,773","shares_owned_after":24970.0,"shares_owned_after_display":"24,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-20","filed_date":"2022-04-21","scope":"insider"},{"id":6687497,"accession":"0001593968-22-000886","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-22-000886","line_url":"/filing/0001593968-22-000886#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3500.0,"shares_display":"3,500","price_per_share":130.81,"price_display":"130.81","price_state":"stated","total_value":457835.0,"total_display":"457,835.00","total_whole":"457,835","shares_owned_after":24970.0,"shares_owned_after_display":"24,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-19","filed_date":"2022-04-21","scope":"insider"},{"id":6460439,"accession":"0001593968-22-000496","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-22-000496","line_url":"/filing/0001593968-22-000496#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1500.0,"shares_display":"1,500","price_per_share":111.14,"price_display":"111.14","price_state":"stated","total_value":166710.0,"total_display":"166,710.00","total_whole":"166,710","shares_owned_after":24970.0,"shares_owned_after_display":"24,970","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-15","filed_date":"2022-02-17","scope":"insider"},{"id":5077815,"accession":"0001593968-21-002380","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-21-002380","line_url":"/filing/0001593968-21-002380#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13500.0,"shares_display":"13,500","price_per_share":152.32,"price_display":"152.32","price_state":"stated","total_value":2056320.0,"total_display":"2,056,320.00","total_whole":"2,056,320","shares_owned_after":18000.0,"shares_owned_after_display":"18,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-08","filed_date":"2021-11-10","scope":"insider"},{"id":4151392,"accession":"0001593968-21-002107","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001593968-21-002107","line_url":"/filing/0001593968-21-002107#line-8","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":120.05,"price_display":"120.05","price_state":"stated","total_value":228095.0,"total_display":"228,095.00","total_whole":"228,095","shares_owned_after":18000.0,"shares_owned_after_display":"18,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-10","filed_date":"2021-09-10","scope":"insider"},{"id":4151387,"accession":"0001593968-21-002107","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001593968-21-002107","line_url":"/filing/0001593968-21-002107#line-6","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":120.05,"price_display":"120.05","price_state":"stated","total_value":60025.0,"total_display":"60,025.00","total_whole":"60,025","shares_owned_after":18000.0,"shares_owned_after_display":"18,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-09","filed_date":"2021-09-10","scope":"insider"},{"id":4151381,"accession":"0001593968-21-002107","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-21-002107","line_url":"/filing/0001593968-21-002107","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":116.5428947368421,"price_display":"116.54","price_state":"stated","total_value":885726.0,"total_display":"885,726.00","total_whole":"885,726","shares_owned_after":18000.0,"shares_owned_after_display":"18,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-08","filed_date":"2021-09-10","scope":"insider","n_lines":2},{"id":5165802,"accession":"0001593968-21-001633","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001593968-21-001633","line_url":"/filing/0001593968-21-001633","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2600.0,"shares_display":"2,600","price_per_share":129.30784615384616,"price_display":"129.31","price_state":"stated","total_value":336200.4,"total_display":"336,200.40","total_whole":"336,200","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-16","filed_date":"2021-06-16","scope":"insider","n_lines":2},{"id":5165778,"accession":"0001593968-21-001633","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-21-001633","line_url":"/filing/0001593968-21-001633#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":900.0,"shares_display":"900","price_per_share":132.52,"price_display":"132.52","price_state":"stated","total_value":119268.0,"total_display":"119,268.00","total_whole":"119,268","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-14","filed_date":"2021-06-16","scope":"insider"},{"id":4109558,"accession":"0001593968-21-001292","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-21-001292","line_url":"/filing/0001593968-21-001292#line-4","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":120.0,"price_display":"120.00","price_state":"stated","total_value":24000.0,"total_display":"24,000.00","total_whole":"24,000","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-12","filed_date":"2021-05-12","scope":"insider"},{"id":4109550,"accession":"0001593968-21-001292","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-21-001292","line_url":"/filing/0001593968-21-001292#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7000.0,"shares_display":"7,000","price_per_share":110.07,"price_display":"110.07","price_state":"stated","total_value":770490.0,"total_display":"770,490.00","total_whole":"770,490","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-10","filed_date":"2021-05-12","scope":"insider"},{"id":5009922,"accession":"0001593968-21-000505","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-21-000505","line_url":"/filing/0001593968-21-000505#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":119.57,"price_display":"119.57","price_state":"stated","total_value":1195700.0,"total_display":"1,195,700.00","total_whole":"1,195,700","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-17","scope":"insider"},{"id":5418507,"accession":"0001593968-21-000122","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-21-000122","line_url":"/filing/0001593968-21-000122#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":104.49,"price_display":"104.49","price_state":"stated","total_value":835920.0,"total_display":"835,920.00","total_whole":"835,920","shares_owned_after":13000.0,"shares_owned_after_display":"13,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-08","filed_date":"2021-01-12","scope":"insider"},{"id":3265606,"accession":"0001593968-20-002179","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001593968-20-002179","line_url":"/filing/0001593968-20-002179#line-8","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":118.0,"shares_display":"118","price_per_share":103.48,"price_display":"103.48","price_state":"stated","total_value":12210.64,"total_display":"12,210.64","total_whole":"12,211","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-10","filed_date":"2020-11-10","scope":"insider"},{"id":3265604,"accession":"0001593968-20-002179","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001593968-20-002179","line_url":"/filing/0001593968-20-002179","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9318.0,"shares_display":"9,318","price_per_share":105.47828718609144,"price_display":"105.48","price_state":"stated","total_value":982846.68,"total_display":"982,846.68","total_whole":"982,847","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-09","filed_date":"2020-11-10","scope":"insider","n_lines":2},{"id":3265600,"accession":"0001593968-20-002179","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-20-002179","line_url":"/filing/0001593968-20-002179#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":564.0,"shares_display":"564","price_per_share":108.15,"price_display":"108.15","price_state":"stated","total_value":60996.6,"total_display":"60,996.60","total_whole":"60,997","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-11-06","filed_date":"2020-11-10","scope":"insider"},{"id":3013967,"accession":"0001593968-20-001858","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001593968-20-001858","line_url":"/filing/0001593968-20-001858#line-2","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":73.3,"price_display":"73.30","price_state":"stated","total_value":146600.0,"total_display":"146,600.00","total_whole":"146,600","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-08","filed_date":"2020-09-10","scope":"insider"},{"id":2207894,"accession":"0000899243-20-018956","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000899243-20-018956","line_url":"/filing/0000899243-20-018956","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":98.74,"price_display":"98.74","price_state":"stated","total_value":789920.0,"total_display":"789,920.00","total_whole":"789,920","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-07-08","filed_date":"2020-07-10","scope":"insider","n_lines":2},{"id":2931373,"accession":"0001593968-20-001492","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001593968-20-001492","line_url":"/filing/0001593968-20-001492#line-6","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2000.0,"shares_display":"2,000","price_per_share":100.0,"price_display":"100.00","price_state":"stated","total_value":200000.0,"total_display":"200,000.00","total_whole":"200,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-16","filed_date":"2020-06-17","scope":"insider"},{"id":2931364,"accession":"0001593968-20-001492","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001593968-20-001492","line_url":"/filing/0001593968-20-001492#line-4","is_derivative":false,"issuer_cik":"0001579829","issuer_name":"Karuna Therapeutics, Inc.","issuer_ticker":"KRTX","issuer_name_source":null,"issuer_url":"/issuer/0001579829","owner_cik":"0001579829","owner_name":"Ignelzi Troy A.","owner_display_name":"Ignelzi Troy A.","owner_url":"/insider/0001579829","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4000.0,"shares_display":"4,000","price_per_share":89.62,"price_display":"89.62","price_state":"stated","total_value":358480.0,"total_display":"358,480.00","total_whole":"358,480","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-06-15","filed_date":"2020-06-17","scope":"insider"}],"collapsed":true,"next_cursor":"2020-06-15|2931364","ledger_fault":false,"count":{"value":53,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":51,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":53},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002012593","name":"Rapport Therapeutics, Inc.","url":"/issuer/0002012593","role":"Officer (Chief Financial Officer)","n_filings":1,"first_seen":"2025-03-13","last_seen":"2025-03-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001771917","name":"Karuna Therapeutics, Inc.","url":"/issuer/0001771917","role":"Officer (Chief Financial Officer)","n_filings":21,"first_seen":"2020-03-04","last_seen":"2023-08-24"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001579829","retrieved_at":"2026-08-23T19:56:41+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}